My watch list  

A phosphorescent cyclometalated iridium(III) complex as mitochondria-targeted theranostic anticancer agent

Publication date:

August 2018

Source:Inorganic Chemistry Communications, Volume 94

Author(s): Qiumiao Xiao, Zizhuo Zhao, Ke Lin, Jinquan Wang

In the present study, a cyclometalated iridium(III) complex, [Ir(ppy)2(HPIP)]Cl (IrT, ppy = 2-phenylpyridine, HPIP = 2-(2-hydroxyphenyl)imidazo[4,5-f]1,10-phenanthroline), was synthesized and characterized. IrT exhibited more cytotoxicity than cisplatin did against several screened cancer cell lines. In particular, the cytotoxicity of IrT against the cisplatin-resistant cell line A549-CP/R is approximately 10 times higher than that of cisplatin. In addition, this complex could perform theranostic functions by simultaneously imaging and tracking mitochondrial morphological changes. Further study suggested that IrT induced changes in the mitochondrial membrane potential and triggered apoptosis via an intrinsic mitochondria-mediated pathway. Thus, IrT exhibited both antitumor and imaging properties, indicating that IrT may be a viable drug candidate as a mitochondria-targeted theranostic anticancer agent.
Graphical abstract

Authors:   Author(s): Qiumiao Xiao, Zizhuo Zhao, Ke Lin, Jinquan Wang
Journal:   Inorganic Chemistry Communications
Year:   2018
Publication date:   24-Jun-2018
Facts, background information, dossiers
More about Elsevier
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE